A Phase 2 interventional study of CBP-201 and placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Connect Biopharm LLC. Completed at 59 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-01.
Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 151st largest by enrollment of the 544 interventional ones that give a count, is one of 37 that started in 2020, is one of 202 in phase 2, and was the 379th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 37 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
Connect Biopharm LLC is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Connect Biopharm LLC has 4 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.
This is a randomized, double-blind, placebo-controlled, dose regimen finding study to assess the efficacy, safety, and steady-state PK profile of CBP-201 administered to eligible adult subjects with moderate to severe atopic dermatitis compared to placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into a treatment period of 16 weeks and a follow-up period of 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have any of the following laboratory abnormalities at Screening:
Have undergone treatment with any of the following:
Have any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CBP-201 Dose 1 subcutaneous (SC) injection
Drug: CBP-201
CBP-201 Dose 2 subcutaneous (SC) injection
Drug: CBP-201
CBP-201 Dose 3 subcutaneous (SC) injection
Drug: CBP-201
subcutaneous (SC) injection
Drug: placebo
CBP-201 subcutaneous(SC) injection.
subcutaneous(SC) injection
Percent Reduction in EASI Score From Baseline to Week 16
EASI=Eczema Area Severity Index is a validated physician score for signs of atopic dermatitis. EASI can range from 0 to 72. An EASI score of 0 indicates clear/no eczema, 0.1 to 1.0 almost clear, 1.1 to 7 mild disease, 7.1 to 21 moderate disease, 21.1 to 50 severe disease, and 51-72 indicates very severe disease. EASI Sub-scale ranges are as follows: Head/neck can range from 0-7.2, Trunk 0-14.4, Upper Extremities 0-21.6, Lower Extremities can range from 0-28.8. To calculate EASI, % involvement is first assessed by body region with an Area involvement Score of 0-6 for each region: 0=0%, 1=1-9%, 2=10-29%, 3=30-39%, 4=50-69%, 5=70-89%, 6=90-100% involvement. Then 4 attributes (Erythema, Edema/Papulation, Excoriation, and Lichenification) are scored for severity (0= none, 1=mild, 2=moderate, 3=severe). A multiplier is applied head/neck=0.1, trunk=0.2, upper extremities= 0.3, lower extremities=0.4. The total EASI score is the sum of 4 regional sub-scores.
Time frame: Reduction from baseline to 16 weeks
vIGA of 0/1 at Week 16
Validated Investigator Global Assessment Score (vIGA) is assigned by the physician based on morphologic presentation of the disease in the clinic. The physician considers extent and severity of erythema, induration/papulation, lichenification, and oozing/crusting. A vIGA Score of 0=Clear, 1=Almost Clear, 2= Mild dermatitis, 3=Moderate dermatitis, and 4= Severe dermatitis. Patients are required to have a baseline IGA of 3 or 4. The response rate or percentage of patients achieving a vIGA of 0 or 1 (improved to clear or almost clear) at week 16 is the outcome.
Time frame: Response Rate at 16 weeks
Patients were recruited based on physician referrral at academic and non-academic clinical centers between Jun 2020 and Sep 2021; 394 patients were screened. The first participant was randomized to treatment on 30 Jun 2020 and the last patient was randomized in April 2021. The last patient last visit was 22 Sept 2021.
| Milestone | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo |
|---|---|---|---|---|
| Started | 57 | 57 | 56 | 56 |
| Completed | 46 | 45 | 50 | 40 |
| Not completed | 11 | 12 | 6 | 16 |
| Withdrew: Adverse event | 1 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 6 | 2 | 5 |
| Withdrew: Physician decision | 0 | 0 | 0 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 5 | 3 | 4 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Withdrew: Patient moving out of town | 1 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
EASI=Eczema Area Severity Index is a validated physician score for signs of atopic dermatitis. EASI can range from 0 to 72. An EASI score of 0 indicates clear/no eczema, 0.1 to 1.0 almost clear, 1.1 to 7 mild disease, 7.1 to 21 moderate disease, 21.1 to 50 severe disease, and 51-72 indicates very severe disease. EASI Sub-scale ranges are as follows: Head/neck can range from 0-7.2, Trunk 0-14.4, Upper Extremities 0-21.6, Lower Extremities can range from 0-28.8. To calculate EASI, % involvement is first assessed by body region with an Area involvement Score of 0-6 for each region: 0=0%, 1=1-9%, 2=10-29%, 3=30-39%, 4=50-69%, 5=70-89%, 6=90-100% involvement. Then 4 attributes (Erythema, Edema/Papulation, Excoriation, and Lichenification) are scored for severity (0= none, 1=mild, 2=moderate, 3=severe). A multiplier is applied head/neck=0.1, trunk=0.2, upper extremities= 0.3, lower extremities=0.4. The total EASI score is the sum of 4 regional sub-scores.
| percent reduction from Baseline | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo |
|---|---|---|---|---|
| Percent Reduction in EASI Score From Baseline to Week 16 | 57.56 ± 4.610 | 63.03 ± 4.961 | 63.50 ± 4.661 | 39.67 ± 4.638 |
Validated Investigator Global Assessment Score (vIGA) is assigned by the physician based on morphologic presentation of the disease in the clinic. The physician considers extent and severity of erythema, induration/papulation, lichenification, and oozing/crusting. A vIGA Score of 0=Clear, 1=Almost Clear, 2= Mild dermatitis, 3=Moderate dermatitis, and 4= Severe dermatitis. Patients are required to have a baseline IGA of 3 or 4. The response rate or percentage of patients achieving a vIGA of 0 or 1 (improved to clear or almost clear) at week 16 is the outcome.
| Participants | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo |
|---|---|---|---|---|
| vIGA of 0/1 at Week 16 | 9 | 16 | 11 | 5 |
Collected over Adverse events were reported from the time the subject signed the informed consent and continued through the scheduled last visit (32 weeks after baseline visit), or if unresolved, until clinical recovery was complete.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CBP-201 150 Q2W | 0/57 (0%) | 1/57 (1.8%) | 26/57 (45.6%) |
| CBP-201 300 Q2W | 0/57 (0%) | 0/57 (0%) | 21/57 (36.8%) |
| CBP-201 300 Q4W | 1/56 (1.8%) | 2/56 (3.6%) | 34/56 (60.7%) |
| Placebo | 0/56 (0%) | 2/56 (3.6%) | 31/56 (55.4%) |
| Event | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo |
|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/57 | 0/57 | 0/56 | 1/56 |
| PneumoniaInfections and infestations | 0/57 | 0/57 | 0/56 | 1/56 |
| Angina pectorisCardiac disorders | 0/57 | 0/57 | 1/56 | 0/56 |
| Cardiac arrestCardiac disorders | 0/57 | 0/57 | 1/56 | 0/56 |
| Rib fractureInjury, poisoning and procedural complications | 0/57 | 0/57 | 1/56 | 0/56 |
| NauseaGastrointestinal disorders | 1/57 | 0/57 | 0/56 | 0/56 |
| VomitingGastrointestinal disorders | 1/57 | 0/57 | 0/56 | 0/56 |
| HeadacheNervous system disorders | 1/57 | 0/57 | 0/56 | 0/56 |
| Event | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo |
|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 7/57 | 5/57 | 14/56 | 8/56 |
| COVID-19Skin and subcutaneous tissue disorders | 4/57 | 2/57 | 1/56 | 4/56 |
| NasopharyngitisInfections and infestations | 1/57 | 3/57 | 2/56 | 4/56 |
| HeadacheNervous system disorders | 3/57 | 2/57 | 4/56 | 0/56 |
| Urinary tract infectionInfections and infestations | 4/57 | 1/57 | 0/56 | 1/56 |
| Upper respiratory tract infectionInfections and infestations | 1/57 | 1/57 | 3/56 | 1/56 |
| Skin infectionInfections and infestations | 0/57 | 0/57 | 1/56 | 3/56 |
| NauseaGastrointestinal disorders | 1/57 | 2/57 | 3/56 | 0/56 |
| Vision blurredEye disorders | 0/57 | 0/57 | 0/56 | 2/56 |
| Back painMusculoskeletal and connective tissue disorders | 0/57 | 0/57 | 2/56 | 2/56 |
| Age, Categorical(Participants) | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 52 | 54 | 52 | 54 | 212 |
| >=65 years | 5 | 3 | 4 | 2 | 14 |
| Age, Continuous(years) | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 39.5 ± 15.98 | 39.6 ± 14.79 | 41.7 ± 15.22 | 39.6 ± 14.79 | 40.1 ± 15.13 |
| Sex: Female, Male(Participants) | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo | Total |
|---|---|---|---|---|---|
| Female | 30 | 27 | 28 | 36 | 121 |
| Male | 27 | 30 | 28 | 20 | 105 |
| Ethnicity (NIH/OMB)(Participants) | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 17 | 24 | 27 | 24 | 92 |
| Not Hispanic or Latino | 40 | 33 | 29 | 32 | 134 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 17 | 9 | 12 | 14 | 52 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 1 | 3 |
| Black or African American | 8 | 7 | 10 | 6 | 31 |
| White | 30 | 38 | 32 | 32 | 132 |
| More than one race | 0 | 1 | 1 | 1 | 3 |
| Unknown or Not Reported | 1 | 1 | 1 | 1 | 4 |
| Region of Enrollment(participants) | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo | Total |
|---|---|---|---|---|---|
| New Zealand | 5 | 3 | 5 | 6 | 19 |
| United States | 40 | 47 | 41 | 44 | 172 |
| China | 11 | 6 | 9 | 6 | 32 |
| Australia | 1 | 1 | 1 | 0 | 3 |
| EASI Score(units on a scale) | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 24.61 ± 10.471 | 27.57 ± 11.776 | 23.08 ± 8.218 | 25.16 ± 9.021 | 25.11 ± 10.042 |
| IGA Score(Participants) | CBP-201 150 Q2W | CBP-201 300 Q2W | CBP-201 300 Q4W | Placebo | Total |
|---|---|---|---|---|---|
| IGA 3 = Moderate disease | 43 | 34 | 40 | 39 | 156 |
| IGA 4 = Severe disease | 14 | 23 | 16 | 17 | 70 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Jul 2021, 12 months.
Results were first posted in Aug 2023, 2 years after primary completion.
Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.
Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CBP-201
Connect Biopharm LLC